Spots Global Cancer Trial Database for Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma
Official Title: A Phase Ib, Multicenter, Open-label Study of HCD122 Administered Intravenously in Combination With Bendamustine in Patients With CD40+ Follicular Lymphoma Who Are Refractory to Rituximab
Study ID: NCT01275209
Conditions
Interventions
Study Description
Brief Summary: This study will assess the safety and efficacy of HCD122 (Lucatumumab) when combined with bendamustine in patients with follicular lymphoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Dana Farber Cancer Institute SC-5, Boston, Massachusetts, United States
Wayne State University/Karmanos Cancer Institute Dept.of KarmanosCancerInst (6), Detroit, Michigan, United States
Duke University Medical Center Duke Hem & Onc, Durham, North Carolina, United States
Sarah Cannon Research Institute SC - 2, Chattanooga, Tennessee, United States
Novartis Investigative Site, Prahran, Victoria, Australia
Novartis Investigative Site, Gent, , Belgium
Novartis Investigative Site, Leuven, , Belgium
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Paris, , France
Novartis Investigative Site, Torino, TO, Italy
Novartis Investigative Site, Barcelona, Cataluña, Spain
Novartis Investigative Site, Madrid, , Spain
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
